13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04952766 (ClinicalTrials.gov) | March 29, 2021 | 16/6/2021 | Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults | Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults | Kidney Transplant;Myeloma;Cancer;Hematologic Malignancy;Multiple Sclerosis;Hypergammaglobulinemia;Malignant Tumor;Hiv;Diabetes Type 2 | Biological: Biological samples | Centre Hospitalier Régional d'Orléans | NULL | Recruiting | 18 Years | N/A | All | 240 | Phase 4 | France |
| 2 | NCT04289675 (ClinicalTrials.gov) | January 1, 2012 | 27/12/2019 | Multiple Sclerosis: Chi3L1 and Treatment Efficacy | Chi3L1: A Marker of Efficacy of Platform Treatments in Relapsing-onset Multiple Sclerosis: A Prognostic Study on Existing Clinical Data and Biological Samples | Multiple Sclerosis | Drug: Interferon-Beta | Central Hospital, Nancy, France | NULL | Completed | 18 Years | 55 Years | All | 63 | NULL |